Clinical trial
Effect of Mepolizumab in Severe Bilateral Nasal Polyps
NCT03085797 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT03085797 |
|---|---|
| Title | Effect of Mepolizumab in Severe Bilateral Nasal Polyps |
| Official title | A Randomised, Double-blind, Parallel Group PhIII Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab as an Add on to Maintenance Treatment in Adults With Severe Bilateral Nasal Polyps - SYNAPSE (StudY in NAsal Polyps Patients to Assess the Safety and Efficacy of Mepolizumab) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Collaborators | CRF Health Industry Bristol-Myers Squibb |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Nasal Polyps |
| Intervention type | Drug |
| Interventions | Mepolizumab, Placebo, Mometasone furoate |
| Enrollment | 414 |
| Start date | May 25, 2017 |
| Primary completion | Dec 11, 2019 |
| Completion | Dec 11, 2019 |
| First posted | Mar 21, 2017 |
| Last update posted | Aug 3, 2021 |
| Countries | Argentina, Australia, Canada, Germany, Netherlands, Romania, Russia, South Korea, Sweden, United Kingdom, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: